{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:28:10Z","timestamp":1790972890337,"version":"4.1.0"},"reference-count":131,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The mitogen-activated protein kinase (MAPK) signaling cascade is fundamental in regulating cellular proliferation and differentiation, cell survival and cell death via apoptosis. Disruption of the MAPK signaling cascade at any point can lead to the evasion of apoptosis and unchecked cell growth and proliferation, leading to oncogenesis. This narrative review describes MAPK pathway dysregulation, its therapeutic targets, and resistance mechanisms. The therapeutic targeting of the MAPK pathway is complex due to the dual context-dependent roles of several kinases in the signaling cascade. Despite the therapeutic effectiveness of MAPK inhibitors, cancer cells develop chemoresistance that needs to be targeted via bypassing (c-Jun N-terminal kinases) JNK, protein kinase AKT and (mammalian target of rapamycin) mTOR signaling cascades, pairing MAPK inhibitors with multiple immune agents and targeting the MAPK pathway downstream of (extracellular signal-regulated kinase) ERK to prevent its reactivation mechanisms using combination therapies, downstream signaling regulators and (Proteolysis Targeting Chimeras) PROTACs. Additionally, MAPK-mediated regulation of ferroptosis is a novel oncological therapeutic targeting strategy for controlling tumor progression. The inhibition of the RAF\/MAPK pathway results in alteration of several key regulators of ferroptosis, including SLCA11, GSH, GPX4 and NCO4A, hence affecting lipid cellular iron concentration and lipid peroxidation. Emerging therapies targeting the MAPK pathway should be designed considering crosstalk, compensatory signaling mechanism activation, the role of ferroptosis and the impact of the tumor microenvironment.<\/jats:p>","DOI":"10.3390\/ijms27010214","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:27:51Z","timestamp":1766586471000},"page":"214","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Targeting the MAPK Pathway in Cancer"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8077-3668","authenticated-orcid":false,"given":"Sultan F.","family":"Kadasah","sequence":"first","affiliation":[{"name":"Department of Biology, Faculty of Science, University of Bisha, P.O. Box 551, Bisha 61922, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","article-title":"Global burden of cancer and associated risk factors in 204 countries and territories, 1980\u20132021: A systematic analysis for the GBD 2021","volume":"17","author":"Wu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Yu, Y., Gong, L., and Ye, J. (2020). The Role of Aberrant Metabolism in Cancer: Insights Into the Interplay Between Cell Metabolic Reprogramming, Metabolic Syndrome, and Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00942"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yue, J., and L\u00f3pez, J.M. (2020). Understanding MAPK Signaling Pathways in Apoptosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072346"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"55684","DOI":"10.18632\/oncotarget.18264","article-title":"The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells","volume":"8","author":"Corre","year":"2017","journal-title":"Oncotarget"},{"key":"ref_5","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis (Review)","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_6","first-page":"854","article-title":"MAPK\/ERK Signaling in Tumorigenesis: Mechanisms of growth, invasion, and angiogenesis","volume":"24","author":"Fei","year":"2025","journal-title":"EXCLI J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: A new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Maik-Rachline, G., Hacohen-Lev-Ran, A., and Seger, R. (2019). Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051194"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s42003-020-01552-6","article-title":"Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies","volume":"4","author":"Sinkala","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: From mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.20892\/j.issn.2095-3941.2019.0137","article-title":"Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy","volume":"16","author":"Li","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-60761-795-2_1","article-title":"The MAP kinase signaling cascades: A system of hundreds of components regulates a diverse array of physiological functions","volume":"661","author":"Keshet","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20230003","DOI":"10.14293\/genint.14.1.004","article-title":"Role of Mitogen-Activated Protein (MAP) Kinase Pathways in Metabolic Diseases","volume":"15","author":"Ng","year":"2024","journal-title":"Genome Integr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1515\/hsz-2014-0257","article-title":"Ras activation revisited: Role of GEF and GAP systems","volume":"396","author":"Hennig","year":"2015","journal-title":"Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1091\/mbc.e03-11-0807","article-title":"The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component","volume":"15","author":"Schulze","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jor.20356","article-title":"Blocking Wnt\/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells","volume":"25","author":"Guo","year":"2007","journal-title":"J. Orthop. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/2211-5463.13619","article-title":"Specificity models in MAPK cascade signaling","volume":"13","author":"Ma","year":"2023","journal-title":"FEBS Open Bio"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1947601911411084","article-title":"Ras in Cancer and Developmental Diseases","volume":"2","author":"Santos","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable Ras: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: From undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Saiki, Y., Jiang, C., Ohmuraya, M., and Furukawa, T. (2021). Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. Cancers, 14.","DOI":"10.3390\/cancers14010071"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.55519\/JAMC-01-10738","article-title":"Analysis of common somatic mutations in colorectal carcinoma and associated dysregulated pathways","volume":"35","author":"Hassan","year":"2023","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.31557\/APJCP.2022.23.11.3725","article-title":"Clinical Significance of Somatic Mutations in RAS\/RAF\/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients","volume":"23","author":"Benmokhtar","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2024.42.3_suppl.185","article-title":"Identification of MAPK and mTOR pathway alterations in HER2-amplified colorectal cancer","volume":"42","author":"Cheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0304-3835(02)00612-2","article-title":"Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer","volume":"191","author":"Wang","year":"2003","journal-title":"Cancer Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41698-024-00726-3","article-title":"Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway","volume":"8","author":"Li","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.2147\/CMAR.S254139","article-title":"Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort","volume":"12","author":"Shen","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1357-2725(01)00093-0","article-title":"The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs)","volume":"33","author":"Barr","year":"2001","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yan, H., He, L., Lv, D., Yang, J., and Yuan, Z. (2024). The Role of the Dysregulated JNK Signaling Pathway in the Pathogenesis of Human Diseases and Its Potential Therapeutic Strategies: A Comprehensive Review. Biomolecules, 14.","DOI":"10.3390\/biom14020243"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41417-020-00290-5","article-title":"c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1","volume":"29","author":"Tian","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1158\/0008-5472.CAN-24-0940","article-title":"Inhibition of JNK Signaling Overcomes Cancer-Associated Fibro-blast-Mediated Immunosuppression and Enhances the Efficacy of Immunotherapy in Bladder Cancer","volume":"84","author":"Cui","year":"2024","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e30841","DOI":"10.1016\/j.heliyon.2024.e30841","article-title":"LINC02257 regulates colorectal cancer liver metastases through JNK pathway","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.21037\/tcr-21-869","article-title":"KDELR2 knockdown synergizes with temozolomide to induce glioma cell apoptosis through the CHOP and JNK\/p38 pathways","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3123968","DOI":"10.1155\/2020\/3123968","article-title":"p38\/JNK Is Required for the Proliferation and Phenotype Changes of Vascular Smooth Muscle Cells Induced by L3MBTL4 in Essential Hypertension","volume":"2020","author":"Hu","year":"2020","journal-title":"Int. J. Hypertens."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/nor068","article-title":"Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides","volume":"13","author":"Yue","year":"2011","journal-title":"Neuro-Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Granato, M., Santarelli, R., Lotti, L.V., Di Renzo, L., Gonnella, R., Garufi, A., Trivedi, P., Frati, L., D\u2019Orazi, G., and Faggioni, A. (2013). JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075965"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Lim\u00f3n, A., Joaquin, M., Caballero, M., Posas, F., and de Nadal, E. (2020). The p38 Pathway: From Biology to Cancer Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21061913"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.bbamcr.2007.03.010","article-title":"p38 MAP-Kinases Pathway Regulation, Function and Role in Human Diseases","volume":"1773","author":"Cuenda","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tibs.2017.02.008","article-title":"p38\u03b3 and p38\u03b4: From Spectators to Key Physiological Players","volume":"42","author":"Cuenda","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0014-5793(95)00346-B","article-title":"Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are phosphorylated in chemically stressed KB cells","volume":"364","author":"Doza","year":"1995","journal-title":"FEBS Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7839144","article-title":"Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms","volume":"267","author":"Raingeaud","year":"1995","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1074\/jbc.273.3.1741","article-title":"Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6","volume":"273","author":"Enslen","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"40641","DOI":"10.1074\/jbc.M007835200","article-title":"Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength","volume":"275","author":"Alonso","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.cellsig.2009.11.020","article-title":"Differential activation of p38MAPK isoforms by MKK6 and MKK3","volume":"22","author":"Remy","year":"2010","journal-title":"Cell. Signal."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e12652","DOI":"10.1111\/aji.12652","article-title":"Mapping out p38MAPK","volume":"77","author":"Bonney","year":"2017","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0092-8674(00)00027-1","article-title":"Requirement for p38alpha in erythropoietin expression: A role for stress kinases in erythropoiesis","volume":"102","author":"Tamura","year":"2000","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/ng2037","article-title":"p38\u03b1 MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation","volume":"39","author":"Ventura","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ccr.2008.06.016","article-title":"Hepatocyte necrosis induced by oxidative stress and IL-1\u03b1 release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis","volume":"14","author":"Sakurai","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.molcel.2016.08.015","article-title":"The N-Terminal Phosphorylation of RB by p38 Bypasses Its Inactivation by CDKs and Prevents Proliferation in Cancer Cells","volume":"64","author":"Gubern","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1038\/onc.2017.274","article-title":"P38 delta MAPK promotes breast cancer progression and lung metastasis by enhancing cell proliferation and cell detachment","volume":"36","author":"Wada","year":"2017","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ccell.2018.04.010","article-title":"Targeting p38\u03b1 Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells","volume":"33","author":"Igea","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1165\/ajrcmb.26.5.4689","article-title":"Selective p38 activation in human non\u2013small cell lung cancer","volume":"26","author":"Greenberg","year":"2002","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.molonc.2013.10.003","article-title":"A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis","volume":"8","author":"Leelahavanichkul","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41417-023-00622-1","article-title":"P38 kinase in gastrointestinal cancers","volume":"30","author":"Phan","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ccr.2014.02.019","article-title":"Dual function of p38\u03b1 MAPK in colon cancer: Suppression of colitis-associated tumor initiation but requirement for cancer cell survival","volume":"25","author":"Gupta","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41586-019-1112-8","article-title":"p38\u03b3 is essential for cell cycle progression and liver tumorigenesis","volume":"568","author":"Manieri","year":"2019","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/0008-5472.CAN-09-2918","article-title":"p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity","volume":"70","author":"Kumar","year":"2010","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00418-014-1300-4","article-title":"c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell line HPAC in a Ca-switch model","volume":"143","author":"Konno","year":"2015","journal-title":"Histochem. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Jema\u00e0, M., Boubaker, N.S., Kerkeni, N., and Huber, S.M. (2025). JNK Inhibition Overcomes Resistance of Metastatic Tetraploid Cancer Cells to Irradiation-Induced Apoptosis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031209"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"27021","DOI":"10.18632\/oncotarget.8395","article-title":"The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo","volume":"7","author":"Okada","year":"2016","journal-title":"Oncotarget"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/srep00516","article-title":"Targeting JNK for therapeutic depletion of stem-like glioblastoma cells","volume":"2","author":"Matsuda","year":"2012","journal-title":"Sci. Rep."},{"key":"ref_63","first-page":"4723","article-title":"Requirement of JNK signaling for self-renewal and tu-mor-initiating capacity of ovarian cancer stem cells","volume":"34","author":"Seino","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1933719115600553","article-title":"Bentamapimod (JNK inhibi-tor AS602801) induces regression of endometriotic lesions in animal models","volume":"23","author":"Palmer","year":"2016","journal-title":"Reprod. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/1940-6207.CAPR-13-0117","article-title":"Licochalcone A, a natural inhibitor of c-Jun N-terminal kinase 1","volume":"7","author":"Yao","year":"2014","journal-title":"Cancer Prev. Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Shi, J., Yang, X., Kang, Q., Lu, J., Denzinger, M., Kornmann, M., and Traub, B. (2022). JNK inhibitor IX restrains pancreatic cancer through p53 and p21. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1006131"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9890","DOI":"10.18632\/oncotarget.7066","article-title":"JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells","volume":"7","author":"Ilmer","year":"2016","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1634\/theoncologist.2012-0391","article-title":"Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma","volume":"18","author":"Luke","year":"2013","journal-title":"Oncologist"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbrc.2019.08.115","article-title":"Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma","volume":"519","author":"Wu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-Class ERK1\/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/neuonc\/noac183","article-title":"The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models","volume":"25","author":"Sigaud","year":"2022","journal-title":"Neuro-Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-23-0805","article-title":"Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials","volume":"24","author":"Jhanji","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: A randomised, open-label, phase 3 trial","volume":"401","author":"Johnson","year":"2023","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation","volume":"387","author":"Riely","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","article-title":"Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: A single-institution experience","volume":"147","author":"Santo","year":"2020","journal-title":"J. Neuro-Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"114008","DOI":"10.1016\/j.ejca.2024.114008","article-title":"A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma","volume":"202","author":"Wei","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ccell.2021.07.023","article-title":"Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"ra90","DOI":"10.1126\/scisignal.2001212","article-title":"The mammalian MAPK\/ERK pathway exhibits properties of a negative feedback amplifier","volume":"3","author":"Sturm","year":"2010","journal-title":"Sci. Signal."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/17425255.2018.1432593","article-title":"Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors","volume":"14","author":"Faghfuri","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.critrevonc.2018.03.005","article-title":"Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors","volume":"125","author":"Wahid","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Lee, S., Rauch, J., and Kolch, W. (2020). Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031102"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature24040","article-title":"PAK signalling drives acquired drug resistance to MAPK inhibi-tors in BRAF-mutant melanomas","volume":"550","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1158\/1078-0432.CCR-13-2823","article-title":"Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival","volume":"20","author":"Zhong","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"24233","DOI":"10.1038\/s41598-024-75089-7","article-title":"Bidirectional effects of morphine on pancreatic cancer progression via the p38\/JNK pathway","volume":"14","author":"Ning","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/0008-5472.CAN-07-2707","article-title":"Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function","volume":"68","author":"Massarweh","year":"2008","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1073\/pnas.1821889116","article-title":"Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway","volume":"116","author":"Gupta","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.18632\/oncotarget.6372","article-title":"Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy re-sistances via modulation of p38\/p53\/p21 and ATM signals","volume":"7","author":"Xie","year":"2016","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"113064","DOI":"10.1016\/j.biopha.2022.113064","article-title":"The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine","volume":"150","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Manzano","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","article-title":"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: An open-label, randomised, phase 3 trial","volume":"23","author":"Cella","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.annonc.2021.10.008","article-title":"VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial","volume":"33","author":"Kelley","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.02.003","article-title":"Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy","volume":"29","author":"Smith","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41419-020-2588-8","article-title":"Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib","volume":"11","author":"Florent","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/bcr2202","article-title":"Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells","volume":"10","author":"Stratford","year":"2008","journal-title":"Breast Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"35761","DOI":"10.18632\/oncotarget.16204","article-title":"Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase","volume":"8","author":"Kosnopfel","year":"2017","journal-title":"Oncotarget"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1158\/1538-7445.AM2022-5378","article-title":"Abstract 5378: PMD-026, a first in class oral RSK inhibitor, demonstrates activity against hormone receptor positive breast cancer with acquired CDK4\/6 inhibitor resistance","volume":"82","author":"Jayanthan","year":"2022","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e13043","DOI":"10.1200\/JCO.2021.39.15_suppl.e13043","article-title":"First-in-human phase 1\/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer","volume":"39","author":"Beeram","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/cas.15280","article-title":"An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer","volume":"113","author":"Ushijima","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13046-023-02755-5","article-title":"Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion","volume":"42","author":"Kosnopfel","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Scheiblecker, L., Kollmann, K., and Sexl, V. (2020). Cdk4\/6 and mapk\u2014Crosstalk as opportunity for cancer treatment. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120418"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/onc.2017.384","article-title":"RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4\/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1","volume":"37","author":"Chen","year":"2017","journal-title":"Oncogene"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1535-7163.MCT-14-0257","article-title":"The CDK4\/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation","volume":"13","author":"Yadav","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/nm.2941","article-title":"Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma","volume":"18","author":"Kwong","year":"2012","journal-title":"Nat. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1158\/1078-0432.CCR-16-1131","article-title":"Preclinical therapeutic synergy of MEK1\/2 and CDK4\/6 in-hibition in neuroblastoma","volume":"23","author":"Hart","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1021\/acs.jmedchem.9b02083","article-title":"Discovery of Selective Small Molecule Degraders of BRAF-V600E","volume":"63","author":"Han","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41467-021-21159-7","article-title":"Mutant-selective degradation by BRAF-targeting PROTACs","volume":"12","author":"Alabi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41589-020-0609-7","article-title":"Functional characterization of a PROTAC directed against BRAF mutant V600E","volume":"16","author":"Posternak","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"20103","DOI":"10.1021\/acs.jmedchem.5c01034","article-title":"ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer","volume":"68","author":"Liu","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Sun, X., Chen, L., Han, J., Cai, W., Li, S., Chen, T., Chen, M., Zhang, H., He, Y., and Zheng, L. (2025). ALOX15 Modulates Ferroptosis via the Reactive Oxygen Species-Mediated MAPK Pathway in Doxorubicin-Induced Cardiotoxicity. Antioxid. Redox Signal., 43.","DOI":"10.1089\/ars.2023.0468"},{"key":"ref_115","first-page":"730","article-title":"HMGB1 regulates erastin-induced ferroptosis via RAS-JNK\/p38 signaling in HL-60\/NRASQ61L cells","volume":"9","author":"Ye","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12964-023-01170-9","article-title":"The emerging roles of MAPK-AMPK in ferroptosis regulatory network","volume":"21","author":"Wang","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.arcmed.2020.04.015","article-title":"P38 MAPK and Nrf2 Activation Mediated Naked Gold Nanoparticle Induced Heme Oxygenase-1 Expression in Rat Aortic Vascular Smooth Muscle Cells","volume":"51","author":"Ko","year":"2020","journal-title":"Arch. Med. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nature05859","article-title":"RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels","volume":"447","author":"Yagoda","year":"2007","journal-title":"Nature"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Riaz, T., Saleem, M.A., Khan, M.U.M., Rashid, M.A.R., and Zubair, M. (2025). Ferroptosis as a Therapeutic Avenue in Triple-Negative Breast Cancer: Mechanistic Insights and Prognostic Potential. Biomedicines, 13.","DOI":"10.3390\/biomedicines13082037"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1535-6108(03)00050-3","article-title":"Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells","volume":"3","author":"Dolma","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.chembiol.2008.02.010","article-title":"Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells","volume":"15","author":"Yang","year":"2008","journal-title":"Chem. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.celrep.2017.02.054","article-title":"Oncogene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine","volume":"18","author":"Poursaitidis","year":"2017","journal-title":"Cell Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1038\/s41467-022-31963-4","article-title":"Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer","volume":"13","author":"Bartolacci","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.21037\/tlcr-21-303","article-title":"Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.7150\/thno.44705","article-title":"Combinative treatment of \u03b2-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e2307","DOI":"10.1038\/cddis.2016.208","article-title":"Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells","volume":"7","author":"Ma","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"100049","DOI":"10.1016\/j.clnves.2025.100049","article-title":"Targeting ferroptosis in cancer therapy: Mechanisms, strategies, and clinical applications","volume":"1","author":"Dai","year":"2025","journal-title":"Cell Investig."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e747","DOI":"10.1002\/ctm2.747","article-title":"Tumour cells are sensitised to ferroptosis via RB1CC1-mediated transcriptional reprogramming","volume":"12","author":"Xue","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6986445","DOI":"10.1155\/2022\/6986445","article-title":"Modulation of the p38 MAPK Pathway by Anisomycin Promotes Ferroptosis of Hepatocellular Carcinoma through Phosphorylation of H3S10","volume":"2022","author":"Chen","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"103419","DOI":"10.1016\/j.redox.2024.103419","article-title":"Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors","volume":"78","author":"Wang","year":"2024","journal-title":"Redox Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T05:15:43Z","timestamp":1767071743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27010214"],"URL":"https:\/\/doi.org\/10.3390\/ijms27010214","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}